Intracavitary Chemotherapy after kidney-Sparing Therapy for Upper Tract Urothelial Carcinoma: A Meta-Analysis
Urology Journal,
Vol. 20 No. 06 (2023),
26 December 2023
,
Page 369-378
https://doi.org/10.22037/uj.v20i.7530
Abstract
Purpose: Intracavitary chemotherapy is one of the current treatment options for kidney-sparing treatment of upper tract urothelial carcinoma (UTUC). The purpose of this meta-analysis was to assess the efficacy and safety of intracavitary perfusion.
Methods: We carefully selected publications for study from four databases (Embase, PubMed, Web of Science, and Scopus) up to January 2023. The R 4.0.4 software was used to calculate the pooled ratio and its 95% confidence intervals (95% CIs). The I2 score was used to test heterogeneity, and the funnel plot was used to estimate the publication bias.
Results: Thirty-four studies with a total of 788 patients were included in this study. The overall survival at a median follow-up of 26.3 months was 87.2% (95% CI 0.80–0.93). The cancer-specific survival at a median follow-up of 30 months was 94.1% (95% CI 0.89–0.98). At a median follow-up of 30 months, the recurrence rate of UTUC was 27.5% (95% CI 0.21–0.34). By subgroup analysis, we found that the recurrence rate in patients with T1 / Ta stage was 35.1% and CIS stage 29.0%. The recurrence rates of BCG, Mitomycin C, and Mitomycin Gel (UGN101) were 31.2%, 41.3% and 12.9%, respectively. The recurrence rates for anterograde and retrograde perfusion were 28.5% and 21.8%, respectively.
Conclusion: With the advent of new drugs, including UGN101, patients with UTUC have a better prognosis. Therefore, kidney preservation therapy for patients with UTUC would be promising.
- upper tract urothelial carcinoma; intracavitary perfusion; kidney-sparing therapy; recurrence rate; meta-analysis
How to Cite
References
Rouprêt M, Babjuk M, Burger M et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol. 2021; 79:62-79.
Ploussard G, Xylinas E, Lotan Y et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol. 2015; 67:803-12.
Lughezzani G, Burger M, Margulis V et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012; 62:100-14.
Cha EK, Shariat SF, Kormaksson M et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012; 61:818-25.
Yakoubi R, Colin P, Seisen T et al. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol. 2014; 40:1629-34.
Smith P, Mandel J, Raman JD. Conservative nephron-sparing treatment of upper-tract tumors. Curr Urol Rep. 2013; 14:102-8.
Bhattacharjee S, Maiti B, Bhattacharya S. First report of charge-transfer induced heat-set hydrogel. Structural insights and remarkable properties. Nanoscale. 2016; 8:11224-33.
Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009; 339:b2700.
Seagroatt V, Stratton I. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. Bmj. 1998; 316:470.
Schoenberg MP, Van Arsdalen KN, Wein AJ. The management of transitional cell carcinoma in solitary renal units. J Urol. 1991; 146:700-2.
Eastham JA, Huffman JL. Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors. J Urol. 1993; 150:324-5.
Sharpe JR, Duffy G, Chin JL. Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol. 1993; 149:457-9.
Martínez-Piñeiro JA, García Matres MJ, Martínez-Piñeiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol. 1996; 156:377-85.
Yokogi H, Wada Y, Mizutani M, Igawa M, Ishibe T. Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol. 1996; 77:676-9.
Keeley FX, Jr., Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol. 1997; 158:2074-7.
Patel A, Fuchs GJ. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol. 1998; 159:71-5.
Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999; 161:772-5.
Nishino Y, Yamamoto N, Komeda H, Takahashi Y, Deguchi T. Bacillus Calmette-Guerin instillation treatment for carcinoma in situ of the upper urinary tract. Bju International. 2000; 85:799-801.
Nonomura N, Ono Y, Nozawa M et al. Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. European Urology. 2000; 38:701-4.
Okubo K, Ichioka K, Terada N et al. Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. Bju International. 2001; 88:343-7.
Irie A, Iwamura M, Kadowaki K et al. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology. 2002; 59:53-7.
Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol. 2003; 169:925-9.
Hayashida Y, Nomata K, Noguchi M et al. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology. 2004; 63:1084-8.
Palou J, Piovesan LF, Huguet J et al. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol. 2004; 172:66-9.
Kojima Y, Tozawa K, Kawai N et al. Long-term outcome of upper urinary tract carcinoma in situ: Effectiveness of nephroureterectomy versus bacillus Calmette-Guerin therapy. International Journal of Urology. 2006; 13:340-4.
Katz MH, Lee MW, Gupta M. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B. J Endourol. 2007; 21:374-7.
Rastinehad AR, Ost MC, Vanderbrink BA et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology. 2009; 73:27-31.
Giannarini G, Kessler TM, Birkhäuser FD, Thalmann GN, Studer UE. Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol. 2011; 60:955-60.
Cutress ML, Stewart GD, Zakikhani P et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012; 110:614-28.
Shapiro EY, Lipsky MJ, Cha DY et al. Outcomes of Intrarenal Bacillus Calmette-Guerin/Interferon-alpha 2B for Biopsy-Proven Upper-Tract Carcinoma in Situ. Journal of Endourology. 2012; 26:1645-50.
Aboumarzouk OM, Somani B, Ahmad S et al. Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann. 2013; 5:184-9.
Motamedinia P, Keheila M, Leavitt DA et al. The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience. J Endourol. 2016; 30:262-7.
Metcalfe M, Wagenheim G, Xiao L et al. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017; 31:946-53.
Balasubramanian A, Metcalfe MJ, Wagenheim G et al. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018; 36:2027-34.
Horiguchi H, Yoneyama T, Hatakeyama S et al. Impact of bacillus Calmette-Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Medical Oncology. 2018; 35.
Tomisaki I, Kubo T, Minato A, Fujimoto N. Efficacy and Tolerability of Bacillus Calmette-Guerin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ. Cancer Investigation. 2018; 36:152-7.
Kleinmann N, Wirth G, Lin JS et al. Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC). Bladder Cancer. 2019; 5:21-9.
Kleinmann N, Matin SF, Pierorazio PM et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020; 21:776-85.
Matin SF, Pierorazio PM, Kleinmann N et al. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022; 207:779-88.
Rosen GH, Nallani A, Muzzey C, Murray KS. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience. J Urol. 2022.
Rose KM, Narang G, Rosen G et al. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2022.
Territo A, Fontanet S, Meneghetti I et al. Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy? Actas Urol Esp (Engl Ed). 2022.
Woldu SL, Labbate C, Murray KS et al. Early experience with UGN-101 for the treatment of upper tract urothelial cancer – A multicenter evaluation of practice patterns and outcomes. Urologic Oncology: Seminars and Original Investigations. 2022.
Paz MM, Zhang X, Lu J, Holmgren A. A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol. 2012; 25:1502-11.
Xylinas E, Rink M, Margulis V et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012; 61:1069-70.
Li WM, Shen JT, Li CC et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol. 2010; 57:963-9.
Seisen T, Colin P, Rouprêt M. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol. 2015; 12:155-66.
Knoedler JJ, Raman JD. Intracavitary therapies for upper tract urothelial carcinoma. Expert Rev Clin Pharmacol. 2018; 11:487-93.
Ko YH, Song PH, Park T, Choi JY. Retrograde pyelography before radical nephroureterectomy for upper tract urothelial carcinoma is associated with intravesical tumor recurrence. Int Braz J Urol. 2020; 46:778-85.
Baboudjian M, Al-Balushi K, Michel F et al. Diagnostic ureteroscopy prior to nephroureterectomy for urothelial carcinoma is associated with a high risk of bladder recurrence despite technical precautions to avoid tumor spillage. World J Urol. 2020; 38:159-65.
Katims AB, Say R, Derweesh I et al. Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). J Urol. 2021; 206:568-76.
Song Y, Du Y, Qin C, Xu T. Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report". World J Urol. 2022; 40:1251-2.
- Abstract Viewed: 651 times
- 7530/pdf Downloaded: 426 times